Practice Areas

“Call for action” of the Israeli Ministry of Health: Marketing exclusivity to biological drugs

August 8, 2018

BREAKING NEWS: The Israeli Ministry of Health is considering amending the Israeli law and possibly introducing marketing exclusivity to biological drugs registered in Israel; therefore, it has recently published a “call for action” inviting the public to take a stand.

On 31 July 2018, the Israeli Ministry of Health (MoH) published a “call for action”, inviting the public to participate in the process of examining the need to amend Section 47D of the Pharmacists’ Ordinance, so it will also cover the protection of confidential data submitted in connection with the registration of biological drugs.

Section 47D of the Pharmacists’ Ordinance already provides marketing exclusivity. However, the MoH took the position, in its letter, that the current regime applies to new chemical entities only.

As indicated in the MoH letter, a team has been assembled, which includes representatives from several government offices, that will conduct a regulatory impact analysis (RIA) procedure, all in accordance with a formal Government decision (no. 2118).

The public was requested to provide its written position in the matter at hand, by
September 16th, 2018 to the following email address: regulation@moh.health.gov.il[1]. Interested parties who wish, additionally, to orally present their position to the team, should indicate such in their submission, and will be invited to a meeting in due course.

Chen Ben Dori - Alkan
Adv., Partner
Chen Ben Dori - Alkan
Chen Ben Dori- Alkan is a partner at Gilat, Bareket & Co.
Eran Bareket
Adv., Senior Partner
Eran Bareket
Eran Bareket is a senior partner at Gilat, Bareket & Co.

[1] The subject line of the email should read: “RIA – Protection of Confidential Information in connection with the registration of biological drugs – consultation with the public”.

These newsletters are provided for general information only. They are not intended as legal advice or opinion and cannot be relied upon as such.

To receive our newsletter please enter your email:

Reinhold Cohn uses cookies to run our site and improve its usability.
By using our site you agree to our use of cookies.

OK Learn more